Comparative Pharmacology
Head-to-head clinical analysis: PENTACARINAT versus PROTOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTACARINAT versus PROTOSTAT.
PENTACARINAT vs PROTOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentamidine is an antiprotozoal agent that interferes with the synthesis of nucleic acids and proteins, possibly through inhibition of dihydrofolate reductase and disruption of polyamine synthesis.
Proto-oncogene tyrosine-protein kinase Src inhibitor; inhibits cell proliferation and induces apoptosis in cancer cells overexpressing Src.
4 mg/kg IV once daily for 21 days for Pneumocystis jirovecii pneumonia (PCP) treatment; 300 mg (or 4 mg/kg) via nebulizer once monthly for PCP prophylaxis.
250 mg orally three times daily after meals for 7-10 days; alternatively, 500 mg twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function, but can be prolonged to 18-24 hours in renal impairment.
8 hours (range 6-10 h); in renal impairment, half-life prolonged up to 20 hours; dose adjustment required for CrCl < 30 mL/min.
Renal: 10-20% unchanged; biliary/fecal: minimal; remainder metabolized.
Renal: 70% as unchanged drug; biliary/fecal: 15% as metabolites; 15% other.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent